Opening New Pathways for Cardiopulmonary Disease Patients

Via Precision Inhaled Drug Delivery

At Aerami Therapeutics, we leverage our proprietary inhalation technology to develop differentiated inhaled therapies for the treatment of cardiopulmonary conditions.

AER-901

Inhaled Imatinib for Pulmonary Arterial Hypertension

A drug-device combination product candidate in Phase 1 for the treatment of pulmonary arterial hypertension

AER-601

Inhaled GLP-1 for Type 2 Diabetes

An inhaled glucagon-like peptide-1 (GLP-1) analog for the treatment of post-prandial hyperglycemia associated with Type 2 diabetes

AER-501

Human Inhaled Insulin for Type 1 and 2 Diabetes

A soft mist inhaled human insulin to improve glycemic control in Type 1 and Type 2 diabetes

Commitment That’s Easy to Take In

Aerami Therapeutics is a clinical stage biopharmaceutical company engaged in the development of differentiated inhaled therapies for the treatment of cardiopulmonary conditions.

About Our Company